Vor Biopharma Key Executives
This section highlights Vor Biopharma's key executives, including their titles and compensation details.
Find Contacts at Vor Biopharma
(Showing 0 of )
Vor Biopharma Earnings
This section highlights Vor Biopharma's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Financial Statements
Access annual & quarterly financial statements for Vor Biopharma, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $- |
| Cost of Revenue | $- | $3.49M | $8.96M | $4.45M | $1.39M |
| Gross Profit | $- | $-3.49M | $-8.96M | $-4.45M | $-1.39M |
| Gross Profit Ratio | 0.00% | - | - | - | - |
| Research and Development Expenses | $93.31M | $94.31M | $64.55M | $47.53M | $31.62M |
| General and Administrative Expenses | $27.88M | $31.72M | $28.87M | $21.49M | $11.75M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $27.88M | $31.72M | $28.87M | $21.49M | $11.75M |
| Other Expenses | $- | $- | $- | $- | $- |
| Operating Expenses | $121.19M | $126.04M | $93.42M | $69.02M | $43.37M |
| Cost and Expenses | $- | $126.04M | $93.42M | $69.02M | $43.37M |
| Interest Income | $4.27M | $8.17M | $1.32M | $119.00K | $29.00K |
| Interest Expense | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $- | $3.49M | $8.96M | $4.45M | $1.39M |
| EBITDA | $-121.19M | $-114.37M | $-90.89M | $-67.58M | $-41.95M |
| EBITDA Ratio | - | - | - | - | - |
| Operating Income | $-121.19M | $-126.04M | $-93.42M | $-69.02M | $-43.37M |
| Operating Income Ratio | - | - | - | - | - |
| Total Other Income Expenses Net | $4.27M | $8.17M | $1.32M | $119.00K | $29.00K |
| Income Before Tax | $-116.91M | $-117.86M | $-92.09M | $-68.90M | $-43.34M |
| Income Before Tax Ratio | - | - | - | - | - |
| Income Tax Expense | $- | $- | $-1.32M | $-119.00K | $427.70K |
| Net Income | $-116.91M | $-117.86M | $-90.77M | $-68.78M | $-43.34M |
| Net Income Ratio | - | - | - | - | - |
| EPS | $-1.70 | $-1.75 | $-2.29 | $-1.85 | $-1.17 |
| EPS Diluted | $-1.70 | $-1.75 | $-2.29 | $-1.85 | $-1.17 |
| Weighted Average Shares Outstanding | 68.71M | 67.19M | 39.55M | 37.17M | 37.13M |
| Weighted Average Shares Outstanding Diluted | 68.71M | 67.19M | 39.55M | 37.17M | 37.13M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $12.23M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cost of Revenue | $- | $- | $900.00K | $943.00K | $892.00K | $2.09M | $1.23M | $2.79M | $3.06M | $2.39M | $575.00K | $426.00K | $1.15M | $1.13M | $354.00K | $633.00K | $- | $- | $- | $- |
| Gross Profit | $- | $- | $-900.00K | $-943.00K | $11.33M | $-2.09M | $-1.23M | $-2.79M | $-3.06M | $-2.39M | $-575.00K | $-426.00K | $-1.15M | $-1.13M | $-354.00K | $-633.00K | $- | $- | $- | $- |
| Gross Profit Ratio | - | 0.00% | - | - | 92.70% | - | - | - | - | - | - | - | - | - | - | - | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $25.35M | $21.82M | $21.82M | $24.32M | $20.90M | $27.61M | $23.90M | $21.91M | $17.06M | $16.88M | $15.33M | $15.28M | $12.69M | $12.93M | $12.97M | $8.94M | $11.33M | $8.14M | $5.97M | $6.17M |
| General and Administrative Expenses | $5.96M | $6.70M | $7.21M | $8.00M | $7.23M | $7.71M | $8.28M | $8.51M | $7.66M | $7.23M | $6.46M | $7.52M | $5.61M | $5.68M | $5.41M | $4.79M | $4.33M | $3.64M | $2.06M | $1.71M |
| Selling and Marketing Expenses | $- | $- | $-900.00K | $-943.00K | $-892.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $5.96M | $6.70M | $6.31M | $7.06M | $6.33M | $7.71M | $8.28M | $8.51M | $7.66M | $7.23M | $6.46M | $7.52M | $5.61M | $5.68M | $5.41M | $4.79M | $4.33M | $3.64M | $2.06M | $1.71M |
| Other Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Operating Expenses | $31.31M | $28.51M | $28.14M | $31.38M | $27.23M | $35.32M | $32.17M | $30.42M | $24.73M | $24.10M | $21.79M | $22.80M | $18.31M | $18.60M | $18.38M | $13.73M | $15.66M | $11.79M | $8.04M | $7.88M |
| Cost and Expenses | $31.31M | $28.51M | $29.04M | $32.33M | $28.12M | $35.32M | $32.17M | $30.42M | $24.73M | $24.10M | $21.79M | $22.80M | $18.31M | $18.60M | $18.38M | $13.73M | $15.66M | $11.79M | $8.04M | $7.88M |
| Interest Income | $599.00K | $954.00K | $1.20M | $1.52M | $1.86M | $2.13M | $2.19M | $1.99M | $815.00K | $313.00K | $133.00K | $63.00K | $54.00K | $48.00K | $10.00K | $7.00K | $- | $- | $- | $29.00K |
| Interest Expense | $- | $- | $- | $- | $1.99M | $- | $- | $- | $- | $313.00K | $133.00K | $63.00K | $- | $- | $- | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $865.00K | $851.00K | $900.00K | $943.00K | $892.00K | $2.09M | $1.23M | $2.79M | $3.06M | $2.39M | $575.00K | $426.00K | $1.15M | $1.13M | $354.00K | $633.00K | $242.00K | $192.00K | $105.00K | $66.00K |
| EBITDA | $-30.45M | $-27.66M | $-29.04M | $-31.38M | $-27.23M | $-34.42M | $-31.30M | $-29.59M | $-24.09M | $-23.21M | $-21.22M | $-22.37M | $-17.91M | $-18.23M | $-18.03M | $-13.42M | $-15.42M | $-11.59M | $-7.93M | $-7.81M |
| EBITDA Ratio | - | - | - | - | -222.74% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | $-31.31M | $-28.51M | $-29.04M | $-32.33M | $-28.12M | $-35.32M | $-32.17M | $-30.42M | $-24.73M | $-24.10M | $-21.79M | $-22.80M | $-18.31M | $-18.60M | $-18.38M | $-13.73M | $-15.66M | $-11.79M | $-8.04M | $-7.88M |
| Operating Income Ratio | - | - | - | - | -230.03% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Other Income Expenses Net | $599.00K | $954.00K | $1.20M | $1.52M | $1.86M | $2.13M | $2.19M | $1.99M | $815.00K | $313.00K | $133.00K | $63.00K | $54.00K | $48.00K | $10.00K | $7.00K | $- | $- | $- | $29.00K |
| Income Before Tax | $-30.71M | $-27.56M | $-27.84M | $-30.80M | $-26.26M | $-33.19M | $-29.98M | $-28.43M | $-23.91M | $-23.79M | $-21.66M | $-22.74M | $-18.25M | $-18.55M | $-18.37M | $-13.72M | $-15.66M | $-11.79M | $-8.04M | $-7.85M |
| Income Before Tax Ratio | - | - | - | - | -214.80% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Income Tax Expense | $- | $- | $- | $899.72K | $565.00K | $1.42M | $3.06M | $-1.99M | $-1.01M | $-313.00K | $-133.00K | $-63.00K | $68.90M | $-756.00K | $- | $-322.00K | $43.34M | $- | $- | $- |
| Net Income | $-30.71M | $-27.56M | $-27.84M | $-30.80M | $-26.26M | $-33.19M | $-29.98M | $-26.44M | $-22.90M | $-23.48M | $-21.53M | $-22.67M | $-18.25M | $-18.55M | $-18.37M | $-13.72M | $-15.66M | $-11.79M | $-8.04M | $-7.85M |
| Net Income Ratio | - | - | - | - | -214.80% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS | $-0.45 | $-0.40 | $-0.41 | $-0.45 | $-0.39 | $-0.49 | $-0.45 | $-0.40 | $-0.49 | $-0.62 | $-0.57 | $-0.61 | $-0.49 | $-0.50 | $-0.50 | $-0.62 | $-0.70 | $-0.97 | $-0.66 | $-0.64 |
| EPS Diluted | $-0.45 | $-0.40 | $-0.41 | $-0.45 | $-0.39 | $-0.49 | $-0.45 | $-0.40 | $-0.49 | $-0.62 | $-0.57 | $-0.61 | $-0.49 | $-0.50 | $-0.50 | $-0.62 | $-0.70 | $-0.97 | $-0.66 | $-0.64 |
| Weighted Average Shares Outstanding | 68.71M | 68.47M | 68.30M | 68.03M | 67.89M | 67.61M | 67.03M | 66.27M | 46.50M | 38.01M | 37.44M | 37.29M | 36.93M | 36.93M | 36.84M | 22.26M | 22.26M | 12.21M | 12.21M | 12.21M |
| Weighted Average Shares Outstanding Diluted | 68.71M | 68.47M | 68.30M | 68.03M | 67.89M | 67.61M | 67.03M | 66.27M | 46.50M | 38.01M | 37.44M | 37.29M | 36.93M | 36.93M | 36.84M | 22.26M | 22.26M | 12.21M | 12.21M | 12.21M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $81.95M | $31.36M | $57.71M | $119.80M | $48.54M |
| Short Term Investments | $9.98M | $105.81M | $172.54M | $87.67M | $- |
| Cash and Short Term Investments | $91.93M | $137.18M | $230.25M | $207.47M | $48.54M |
| Net Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Other Current Assets | $4.58M | $3.63M | $6.71M | $6.93M | $567.00K |
| Total Current Assets | $96.51M | $140.80M | $236.95M | $214.40M | $49.11M |
| Property Plant Equipment Net | $41.59M | $50.10M | $57.08M | $22.52M | $21.84M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $2.41M | $2.41M | $1.56M |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $4.80M | $7.22M | $2.92M | $3.25M | $3.40M |
| Total Non-Current Assets | $46.38M | $57.32M | $62.42M | $28.19M | $26.80M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $142.89M | $198.13M | $299.37M | $242.59M | $75.91M |
| Account Payables | $1.50M | $815.00K | $1.77M | $1.54M | $2.36M |
| Short Term Debt | $4.21M | $3.83M | $6.54M | $3.68M | $1.73M |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $6.33M | $6.26M |
| Other Current Liabilities | $12.89M | $10.93M | $4.80M | $4.93M | $6.12M |
| Total Current Liabilities | $18.61M | $15.57M | $13.12M | $10.15M | $10.21M |
| Long Term Debt | $27.61M | $31.83M | $71.28M | $32.35M | $34.86M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $-35.64M | $-16.17M | $-17.43M |
| Total Non-Current Liabilities | $27.61M | $31.83M | $35.64M | $16.17M | $17.43M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $46.23M | $47.40M | $48.76M | $26.33M | $27.64M |
| Preferred Stock | $- | $- | $- | $242.59M | $107.34M |
| Common Stock | $13.00K | $7.00K | $7.00K | $4.00K | $1.00K |
| Retained Earnings | $-456.99M | $-340.08M | $-222.22M | $-130.12M | $-61.22M |
| Accumulated Other Comprehensive Income Loss | $22.00K | $-77.00K | $-770.00K | $-242.59M | $- |
| Other Total Stockholders Equity | $553.62M | $490.87M | $473.59M | $346.38M | $2.16M |
| Total Stockholders Equity | $96.66M | $150.72M | $250.61M | $216.26M | $48.27M |
| Total Equity | $96.66M | $150.72M | $250.61M | $216.26M | $48.27M |
| Total Liabilities and Stockholders Equity | $142.89M | $198.13M | $299.37M | $242.59M | $75.91M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $142.89M | $198.13M | $299.37M | $242.59M | $75.91M |
| Total Investments | $9.98M | $105.81M | $172.54M | $87.67M | $1.56M |
| Total Debt | $31.83M | $35.66M | $38.91M | $18.01M | $18.29M |
| Net Debt | $-50.12M | $4.30M | $-18.79M | $-101.79M | $-30.25M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $81.95M | $52.80M | $76.08M | $44.96M | $31.36M | $45.03M | $32.21M | $42.45M | $57.71M | $60.83M | $62.95M | $90.04M | $119.80M | $143.03M | $169.52M | $262.57M | $48.54M | $63.60M | $72.91M | $-6.47M |
| Short Term Investments | $9.98M | $10.01M | $9.86M | $62.52M | $105.81M | $115.07M | $154.69M | $167.75M | $172.54M | $75.24M | $88.14M | $91.58M | $87.67M | $82.93M | $75.12M | $- | $- | $- | $- | $12.93M |
| Cash and Short Term Investments | $91.93M | $62.81M | $85.94M | $107.48M | $137.18M | $160.10M | $186.90M | $210.20M | $230.25M | $136.07M | $151.09M | $181.62M | $207.47M | $225.97M | $244.63M | $262.57M | $48.54M | $63.60M | $72.91M | $6.47M |
| Net Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Assets | $4.58M | $4.49M | $4.32M | $4.34M | $6.78M | $4.34M | $4.49M | $6.70M | $6.71M | $6.66M | $7.75M | $8.69M | $6.93M | $6.10M | $4.63M | $3.70M | $567.00K | $1.92M | $1.90M | $- |
| Total Current Assets | $96.51M | $67.30M | $90.26M | $111.82M | $140.80M | $164.44M | $191.39M | $216.90M | $236.95M | $142.73M | $158.84M | $190.30M | $214.40M | $232.07M | $249.26M | $266.26M | $49.11M | $65.52M | $74.81M | $6.47M |
| Property Plant Equipment Net | $41.59M | $43.77M | $45.86M | $47.98M | $50.10M | $52.09M | $53.91M | $55.43M | $57.08M | $58.35M | $60.97M | $33.36M | $22.52M | $22.01M | $22.21M | $22.53M | $21.84M | $21.09M | $19.81M | $- |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $2.41M | $2.41M | $2.41M | $2.41M | $2.41M | $2.41M | $2.41M | $2.41M | $2.41M | $2.41M | $87.67M | $2.41M | $1.56M | $1.56M | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $11.70M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $4.80M | $4.92M | $3.06M | $4.82M | $4.81M | $4.09M | $3.27M | $2.79M | $2.92M | $2.88M | $2.38M | $8.19M | $-82.00M | $2.14M | $2.11M | $2.58M | $4.96M | $1.91M | $1.56M | $-6.47M |
| Total Non-Current Assets | $46.38M | $48.70M | $51.33M | $55.21M | $69.03M | $58.59M | $59.59M | $60.63M | $62.42M | $63.64M | $65.77M | $43.97M | $28.19M | $26.56M | $25.88M | $26.67M | $26.80M | $23.00M | $21.37M | $-6.47M |
| Other Assets | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $0 | $-0 | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $142.89M | $115.99M | $141.59M | $167.03M | $209.83M | $223.02M | $250.99M | $277.53M | $299.37M | $206.37M | $224.62M | $234.27M | $242.59M | $258.63M | $275.14M | $292.94M | $75.91M | $88.53M | $96.19M | $- |
| Account Payables | $1.50M | $1.32M | $2.01M | $2.33M | $815.00K | $1.31M | $1.65M | $3.22M | $1.77M | $824.00K | $1.27M | $1.25M | $1.54M | $1.96M | $2.37M | $2.41M | $2.36M | $2.32M | $1.66M | $- |
| Short Term Debt | $4.21M | $4.16M | $8.23M | $3.96M | $7.66M | $7.49M | $7.38M | $7.43M | $3.27M | $7.51M | $8.86M | $14.56M | $3.68M | $2.29M | $2.33M | $2.31M | $1.73M | $713.00K | $- | $- |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- | $9.92M | $7.11M | $- | $- | $- | $- | $- | $6.33M | $5.68M | $4.29M | $4.39M | $6.26M | $4.15M | $- | $- |
| Other Current Liabilities | $12.89M | $8.87M | $3.57M | $6.93M | $7.10M | $6.59M | $3.69M | $1.94M | $8.07M | $2.76M | $2.14M | $2.33M | $4.93M | $4.96M | $3.61M | $3.92M | $6.12M | $4.57M | $2.29M | $- |
| Total Current Liabilities | $18.61M | $14.35M | $13.80M | $13.21M | $15.57M | $15.39M | $12.72M | $12.58M | $13.12M | $11.10M | $12.26M | $18.14M | $10.15M | $9.21M | $8.30M | $8.63M | $10.21M | $7.60M | $3.95M | $- |
| Long Term Debt | $27.61M | $28.69M | $29.71M | $30.78M | $63.66M | $65.71M | $67.64M | $69.48M | $35.64M | $73.07M | $74.76M | $43.35M | $32.35M | $32.93M | $33.46M | $34.24M | $34.86M | $17.73M | $17.90M | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $11.70M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $- | $- | $-31.83M | $-32.85M | $-33.82M | $-34.74M | $- | $-36.54M | $-37.38M | $-21.68M | $-16.17M | $-16.46M | $-16.73M | $-17.12M | $-17.43M | $- | $- | $- |
| Total Non-Current Liabilities | $27.61M | $28.69M | $29.71M | $30.78M | $43.53M | $32.85M | $33.82M | $34.74M | $35.64M | $36.54M | $37.38M | $21.68M | $16.17M | $16.46M | $16.73M | $17.12M | $17.43M | $17.73M | $17.90M | $- |
| Other Liabilities | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $46.23M | $43.04M | $43.51M | $43.99M | $59.10M | $48.24M | $46.54M | $47.32M | $48.76M | $47.64M | $49.64M | $39.82M | $26.33M | $25.68M | $25.04M | $25.75M | $27.64M | $25.33M | $21.84M | $- |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $258.63M | $275.14M | $292.94M | $107.34M | $107.34M | $107.34M | $25.07M |
| Common Stock | $13.00K | $7.00K | $7.00K | $7.00K | $7.00K | $7.00K | $7.00K | $7.00K | $7.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $1.00K | $- | $- | $- |
| Retained Earnings | $-456.99M | $-426.28M | $-398.72M | $-370.88M | $-340.08M | $-313.82M | $-280.63M | $-250.65M | $-222.22M | $-198.31M | $-174.52M | $-152.86M | $-130.12M | $-111.87M | $-93.32M | $-74.95M | $-61.22M | $-45.56M | $-33.78M | $- |
| Accumulated Other Comprehensive Income Loss | $22.00K | $68.00K | $-70.00K | $-87.00K | $-77.00K | $-280.00K | $-436.00K | $-174.00K | $-770.00K | $-1.18M | $-1.33M | $-1.07M | $- | $-258.63M | $-275.14M | $-292.94M | $- | $- | $- | $-17.43M |
| Other Total Stockholders Equity | $553.62M | $499.16M | $496.87M | $494.00M | $490.87M | $488.87M | $485.51M | $481.03M | $473.59M | $358.21M | $350.81M | $348.38M | $346.38M | $603.46M | $618.56M | $342.13M | $2.16M | $1.42M | $783.00K | $- |
| Total Stockholders Equity | $96.66M | $72.95M | $98.08M | $123.03M | $150.72M | $174.78M | $204.45M | $230.22M | $250.61M | $158.73M | $174.97M | $194.45M | $216.26M | $232.96M | $250.11M | $267.19M | $48.27M | $63.19M | $74.34M | $7.64M |
| Total Equity | $96.66M | $72.95M | $98.08M | $123.03M | $150.72M | $174.78M | $204.45M | $230.22M | $250.61M | $158.73M | $174.97M | $194.45M | $216.26M | $232.96M | $250.11M | $267.19M | $48.27M | $63.19M | $74.34M | $7.64M |
| Total Liabilities and Stockholders Equity | $142.89M | $115.99M | $141.59M | $167.03M | $209.83M | $223.02M | $250.99M | $277.53M | $299.37M | $206.37M | $224.62M | $234.27M | $242.59M | $258.63M | $275.14M | $292.94M | $75.91M | $88.53M | $96.19M | $7.64M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $142.89M | $115.99M | $141.59M | $167.03M | $209.83M | $223.02M | $250.99M | $277.53M | $299.37M | $206.37M | $224.62M | $234.27M | $242.59M | $258.63M | $275.14M | $292.94M | $75.91M | $88.53M | $96.19M | $7.64M |
| Total Investments | $9.98M | $10.01M | $12.28M | $64.93M | $108.23M | $115.07M | $154.69M | $167.75M | $172.54M | $75.24M | $88.14M | $91.58M | $87.67M | $82.93M | $75.12M | $1.56M | $- | $- | $- | $12.93M |
| Total Debt | $31.83M | $32.85M | $33.82M | $34.74M | $35.66M | $36.60M | $37.51M | $38.45M | $38.91M | $40.29M | $41.81M | $28.96M | $18.01M | $17.61M | $17.89M | $18.28M | $18.29M | $18.44M | $17.90M | $- |
| Net Debt | $-50.12M | $-19.94M | $-42.26M | $-10.22M | $4.30M | $-8.43M | $5.30M | $-4.00M | $-18.79M | $-20.53M | $-21.14M | $-61.08M | $-101.79M | $-125.42M | $-151.62M | $-244.29M | $-30.25M | $-45.16M | $-55.01M | $6.47M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-116.91M | $-117.86M | $-92.09M | $-68.90M | $-43.34M |
| Depreciation and Amortization | $3.53M | $3.49M | $2.52M | $1.43M | $605.00K |
| Deferred Income Tax | $- | $- | $- | $- | $- |
| Stock Based Compensation | $9.85M | $13.36M | $10.70M | $4.32M | $1.34M |
| Change in Working Capital | $5.00K | $650.00K | $-12.69M | $-9.19M | $4.32M |
| Accounts Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Accounts Payables | $- | $2.85M | $1 | $405.00K | $5.82M |
| Other Working Capital | $5.00K | $-2.20M | $-12.69M | $-9.59M | $-1.50M |
| Other Non Cash Items | $3.87M | $67.00K | $6.42M | $3.19M | $782.00K |
| Net Cash Provided by Operating Activities | $-99.66M | $-100.29M | $-85.14M | $-69.14M | $-36.29M |
| Investments in Property Plant and Equipment | $-229.00K | $-1.07M | $-8.46M | $-3.89M | $-4.16M |
| Acquisitions Net | $- | $- | $- | $- | $- |
| Purchases of Investments | $-9.91M | $-74.92M | $-123.19M | $-87.76M | $- |
| Sales Maturities of Investments | $107.00M | $147.00M | $37.56M | $- | $- |
| Other Investing Activities | $- | $- | $-0 | $-87.76K | $- |
| Net Cash Used for Investing Activities | $96.86M | $71.01M | $-94.09M | $-91.65M | $-4.16M |
| Debt Repayment | $- | $- | $- | $- | $- |
| Common Stock Issued | $55.83M | $4.58M | $115.97M | $189.20M | $82.27M |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $-2.43M | $-1.64M | $1.17M | $43.71M | $82.53M |
| Net Cash Used Provided by Financing Activities | $53.39M | $2.94M | $117.14M | $232.91M | $82.53M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $50.59M | $-26.35M | $-62.09M | $72.12M | $42.07M |
| Cash at End of Period | $84.36M | $33.77M | $60.12M | $122.21M | $50.10M |
| Cash at Beginning of Period | $33.77M | $60.12M | $122.21M | $50.10M | $8.03M |
| Operating Cash Flow | $-99.66M | $-100.29M | $-85.14M | $-69.14M | $-36.29M |
| Capital Expenditure | $-229.00K | $-1.07M | $-8.46M | $-3.89M | $-4.16M |
| Free Cash Flow | $-99.89M | $-101.36M | $-93.61M | $-73.04M | $-40.45M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-30.71M | $-27.56M | $-27.84M | $-30.80M | $-26.26M | $-33.19M | $-29.98M | $-28.43M | $-23.91M | $-23.79M | $-21.66M | $-22.74M | $-18.25M | $-18.55M | $-18.37M | $-13.72M | $-15.66M | $-11.79M | $-8.04M | $-7.85M |
| Depreciation and Amortization | $865.00K | $820.00K | $900.00K | $943.00K | $892.00K | $-1.42M | $3.19M | $837.00K | $632.00K | $892.00K | $575.00K | $426.00K | $395.00K | $374.00K | $354.00K | $311.00K | $242.00K | $192.00K | $105.00K | $66.00K |
| Deferred Income Tax | $- | $- | $- | $- | $-3.51M | $5.45M | $1.04M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Stock Based Compensation | $1.71M | $2.26M | $2.79M | $3.08M | $1.89M | $3.16M | $4.24M | $4.07M | $3.88M | $3.33M | $1.74M | $1.75M | $1.20M | $1.15M | $1.07M | $891.00K | $594.00K | $483.00K | $153.00K | $112.00K |
| Change in Working Capital | $2.82M | $-99.00K | $1.41M | $-4.12M | $-779.00K | $1.27M | $1.65M | $-1.49M | $-1.20M | $-874.00K | $-7.30M | $-3.32M | $-1.83M | $-1.11M | $-802.00K | $-5.45M | $872.00K | $2.54M | $-685.00K | $1.59M |
| Accounts Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $- | $485.00K | $551.00K | $-2.48M | $172.00K | $2.66M | $107.00K | $-88.00K | $1 | $931.00K | $-751.00K | $-722.00K | $405.00K | $1.09M | $1.68M | $-2.44M | $5.82M | $- | $- | $- |
| Other Working Capital | $2.82M | $-584.00K | $857.00K | $-1.64M | $-951.00K | $-1.39M | $1.54M | $88.00K | $-1.20M | $-1.80M | $-6.54M | $-2.60M | $-2.23M | $-1.11M | $-802.00K | $-3.01M | $-4.95M | $2.54M | $-685.00K | $-347.00K |
| Other Non Cash Items | $1.26M | $1.29M | $4.93M | $7.88M | $3.73M | $-3.16M | $-4.24M | $751.00K | $2.25M | $1.54M | $1.65M | $985.00K | $893.00K | $790.00K | $1.19M | $322.00K | $321.00K | $322.00K | $139.00K | $1.93M |
| Net Cash Provided by Operating Activities | $-24.06M | $-23.29M | $-21.85M | $-30.46M | $-24.03M | $-27.90M | $-24.10M | $-24.27M | $-18.35M | $-18.90M | $-24.99M | $-22.90M | $-17.59M | $-17.34M | $-16.57M | $-17.65M | $-13.63M | $-8.24M | $-8.33M | $-6.08M |
| Investments in Property Plant and Equipment | $-72.00K | $-34.00K | $-9.00K | $-114.00K | $-111.00K | $-465.00K | $-399.00K | $-94.00K | $-321.00K | $-298.00K | $-5.83M | $-2.01M | $-1.17M | $-636.00K | $-919.00K | $-1.17M | $-1.48M | $-1.59M | $-552.00K | $-545.00K |
| Acquisitions Net | $- | $- | $- | $- | $61.63K | $-41.00K | $-14.04K | $-6.59K | $96.72K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $-1.00K | $-9.91M | $-16.55M | $1.00K | $-34.96M | $-23.41M | $-118.14M | $- | $- | $-5.04M | $-4.79M | $-7.85M | $-75.12M | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $53.00M | $54.00M | $27.00M | $41.00M | $49.00M | $30.00M | $21.43M | $13.00M | $3.13M | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $- | $- | $44.09M | $-1 | $41.00K | $14.04K | $6.59K | $-96.72K | $13.00K | $3.13K | $-5.04M | $-4.79M | $-7.85M | $-75.12M | $- | $- | $- | $- | $- |
| Net Cash Used for Investing Activities | $-72.00K | $-34.00K | $52.99M | $43.97M | $10.34M | $40.54M | $13.64M | $6.50M | $-97.04M | $12.70M | $-2.70M | $-7.05M | $-5.95M | $-8.49M | $-76.04M | $-1.17M | $-1.48M | $-1.59M | $-552.00K | $-545.00K |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $55.53M | $111.00K | $-92.00K | $278.00K | $47.00K | $392.00K | $579.00K | $3.62M | $111.63M | $3.84M | $504.00K | $200.00K | $-1.00K | $201.00K | $-445.00K | $189.20M | $82.27M | $- | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $-22.00K | $- | $- | $-400.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $-2.24M | $-70.00K | $61.00K | $-182.00K | $40.00K | $-216.00K | $-361.00K | $-1.10M | $631.00K | $234.00K | $100.00K | $200.00K | $308.00K | $201.00K | $-445.00K | $43.65M | $46.00K | $526.00K | $64.19M | $17.76M |
| Net Cash Used Provided by Financing Activities | $53.29M | $41.00K | $-31.00K | $96.00K | $25.00K | $176.00K | $218.00K | $2.52M | $112.26M | $4.08M | $604.00K | $200.00K | $307.00K | $201.00K | $-445.00K | $232.85M | $46.00K | $526.00K | $64.19M | $17.76M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $-4.83M | $-9.65M | $14.48M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $29.15M | $-23.28M | $31.11M | $13.60M | $-13.67M | $12.81M | $-38.22M | $-15.25M | $-3.12M | $-2.12M | $-27.09M | $-29.76M | $-23.23M | $-25.63M | $-93.05M | $214.03M | $-15.06M | $-9.31M | $55.31M | $11.13M |
| Cash at End of Period | $84.36M | $55.21M | $76.08M | $44.96M | $31.36M | $47.44M | $4.24M | $44.87M | $60.12M | $63.24M | $65.36M | $92.45M | $122.21M | $145.45M | $171.07M | $264.13M | $50.10M | $65.16M | $74.47M | $19.16M |
| Cash at Beginning of Period | $55.21M | $78.49M | $44.96M | $31.36M | $45.03M | $34.62M | $42.45M | $60.12M | $63.24M | $65.36M | $92.45M | $122.21M | $145.45M | $171.07M | $264.13M | $50.10M | $65.16M | $74.47M | $19.16M | $8.03M |
| Operating Cash Flow | $-24.06M | $-23.29M | $-21.85M | $-30.46M | $-24.03M | $-27.90M | $-24.10M | $-24.27M | $-18.35M | $-18.90M | $-24.99M | $-22.90M | $-17.59M | $-17.34M | $-16.57M | $-17.65M | $-13.63M | $-8.24M | $-8.33M | $-6.08M |
| Capital Expenditure | $-72.00K | $-34.00K | $-9.00K | $-114.00K | $-111.00K | $-465.00K | $-399.00K | $-94.00K | $-321.00K | $-298.00K | $-5.83M | $-2.01M | $-1.17M | $-636.00K | $-919.00K | $-1.17M | $-1.48M | $-1.59M | $-552.00K | $-545.00K |
| Free Cash Flow | $-24.14M | $-23.32M | $-21.86M | $-30.58M | $-24.14M | $-28.36M | $-24.50M | $-24.36M | $-18.67M | $-19.20M | $-30.82M | $-24.91M | $-18.75M | $-17.98M | $-17.48M | $-18.82M | $-15.11M | $-9.83M | $-8.88M | $-6.63M |
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
$0.68
Stock Price
$84.41M
Market Cap
159
Employees
Cambridge, MA
Location
Revenue (FY 2024)
$-
0.0% YoY
Net Income (FY 2024)
$-116.91M
0.8% YoY
EPS (FY 2024)
$-1.70
2.9% YoY
Free Cash Flow (FY 2024)
$-99.89M
1.5% YoY
Profitability
Gross Margin
0.0%
Net Margin
0.0%
ROE
-120.9%
ROA
-81.8%
Valuation
P/E Ratio
-0.65
P/S Ratio
0.00
EV/EBITDA
-0.22
Market Cap
$84.41M
Revenue & Net Income
Profit Margins
Cash Flow Summary
Operating Cash Flow
$-99.66M
0.6% YoY
Free Cash Flow
$-99.89M
1.5% YoY
Balance Sheet Summary
Total Assets
$142.89M
-27.9% YoY
Total Debt
$31.83M
10.7% YoY
Shareholder Equity
$96.66M
-37.3% YoY
Dividend Overview
No Dividend Data
Vor Biopharma Inc. doesn't currently pay dividends.
Vor Biopharma Dividends
Explore Vor Biopharma's dividend history, including dividend yield, payout ratio, and historical payments.
Vor Biopharma News
Read the latest news about Vor Biopharma, including recent articles, headlines, and updates.
Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update
VCAR33 clinical data update planned for first half of 2025 and trem-cel + Mylotarg clinical data update planned for second half of 2025 Anticipate initiation of the first trem-cel+VCAR33 Treatment System clinical trial in second half of 2025 $55.6 million private placement completed in December 2024 CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period and full year ended December 31, 2024, and provided a business update.
Vor Bio Presents Novel Research Highlighting Opportunities and Challenges Facing Institutions Enrolling Patients in Cell and Gene Therapy Trials
Clinical trial complexity, logistical challenges associated with treatments, and resource constraints at trial sites cited as top factors that delay enrollment into cell and gene therapy (CGT) clinical trials Despite the increased time required to obtain informed consent, 100% of those surveyed continue to offer patients these innovative investigational treatment options CAMBRIDGE, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today presented novel research evaluating the patient experience and barriers to enrollment and participation in cell and gene therapy (CGT) trials.
Vor Bio to Participate in the Oppenheimer's 35th Annual Healthcare Life Sciences Conference
CAMBRIDGE, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host virtual 1x1 investor meetings at the Oppenheimer's 35th Annual Healthcare Life Sciences Conference.
Vor Biopharma Inc. (VOR)'s Technical Outlook is Bright After Key Golden Cross
Vor Biopharma Inc. (VOR) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, VOR's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.
Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors
CAMBRIDGE, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Mr. Erez Kalir to its Board of Directors. The appointment represents a new seat on Vor Bio's Board of Directors, which has been created in connection with the recent private investment in public equity financing (PIPE) which was led by Reid Hoffman. Mr. Kalir will serve as the director designee of Reprogrammed Interchange, LLC, Mr. Hoffman's investment fund.
Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design
CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced updated clinical data from its ongoing Phase 1/2 VBP101 study of patients with relapsed/refractory AML receiving trem-cel followed by Mylotarg™. The data, which was presented in a poster at the American Society of Hematology (ASH) Annual Meeting on Sunday, December 8th, demonstrated durable engraftment, shielding from Mylotarg on-target toxicity, a broadened Mylotarg therapeutic window, and early evidence of improved relapse free survival compared to published high-risk AML comparators.
Vor Bio price target lowered to $8 from $10 at Oppenheimer
Oppenheimer analyst Matthew Biegler lowered the firm's price target on Vor Bio to $8 from $10 and keeps an Outperform rating on the shares following the Q3 report. The firm cites updated spending estimates based on guidance from management for the target. It acknowledges Vor's "financial overhang," but still views the company as a "deeply discounted innovator in the biotech sector."
Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer
CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Han Choi, M.D., LL.M., as its new Chief Financial Officer, effective immediately. Dr. Choi will join the Vor Bio leadership team and will report directly to the company's President and Chief Executive Officer, Dr. Robert Ang.
New Clinical Data Validates Vor Bio's Approach of Using Shielded Transplants to Deliver Targeted Therapies
CAMBRIDGE, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced new clinical data from its ongoing Phase 1/2 VBP101 study of patients with relapsed/refractory AML receiving trem-cel followed by Mylotarg™. The data demonstrated reliable engraftment, shielding from Mylotarg on-target toxicity, a broadened Mylotarg therapeutic window, and early evidence of patient benefit.
Vor Bio Reports Second Quarter 2024 Financial Results and Provides Company Update
CAMBRIDGE, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended June 30, 2024, and provided a corporate update.
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of July 31, 2024, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 1,250 shares of Vor Bio's common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 1,875 shares of Vor Bio's common stock to one newly hired employee. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”).
Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update
CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended March 31, 2024, and provided a business update.
Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Fouad Namouni, M.D., to its Board of Directors. Dr. Namouni currently serves as President of Research & Development at Blueprint Medicines, bringing a wealth of industry experience and expertise to Vor Bio's Board.
Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
CAMBRIDGE, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period and full year ended December 31, 2023, and provided a business update.
Vor Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
CAMBRIDGE, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host virtual 1x1 investor meetings at the Oppenheimer 34th Annual Healthcare Life Sciences Conference.
Vor Bio Doses First AML Patient with VCAR33 (ALLO) and Provides Corporate Update
CAMBRIDGE, Mass., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, announced today it has dosed the first patient in VBP301, its Phase 1/2, multicenter, open-label, first-in-human study of VCAR33ALLO. The Company has extended its cash runway into the second half of 2025.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for VOR.